The US Justice Department has officially moved certain marijuana products into Schedule III of federal drug law, a significant policy shift that could transform medical research, patient access, and the cannabis industry. This change applies to FDA-approved marijuana products and those sold under state medical marijuana licenses, effectively easing research and regulatory barriers. Schedule III is less restrictive than Schedule I, which is reserved for substances with high abuse potential and no accepted medical use. This reclassification allows for better clarity for healthcare providers and businesses, potentially improving patient access to approved therapies. However, the broader rescheduling of marijuana remains uncertain, with a new administrative hearing scheduled for June 29, 2026. The immediate effects of this change are limited, but it may signal a shift toward greater acceptance and regulation of cannabis, attracting attention from investors and businesses in the sector. The Acting Attorney General emphasized that this move aligns with efforts to enhance access to medical treatment options for Americans, while the Drug Enforcement Administration (DEA) continues to enforce laws against illegal trafficking.